IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies

BACKGROUND: Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous pemphigoid, urticaria). In oncology, pruritus-associated cutaneous adverse events (paCAEs) are frequent with immune checkpoint inhibitors (...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrios, D. M., Phillips, G. S., Geisler, A. N., Trelles, S. R., Markova, A., Noor, S. J., Quigley, E. A., Haliasos, H. C., Moy, A. P., Schram, A. M., Bromberg, J., Funt, S. A., Voss, M. H., Drilon, A., Hellmann, M. D., Comen, E. A., Narala, S., Patel, A. B., Wetzel, M., Jung, J. Y., Leung, D. Y. M., Lacouture, M. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282165/
https://www.ncbi.nlm.nih.gov/pubmed/33667669
http://dx.doi.org/10.1016/j.annonc.2021.02.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282165/
https://www.ncbi.nlm.nih.gov/pubmed/33667669
http://dx.doi.org/10.1016/j.annonc.2021.02.016

Ejemplares similares